Source:http://linkedlifedata.com/resource/pubmed/id/15054036
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2004-7-2
|
| pubmed:abstractText |
In myelodysplastic syndromes (MDS), anemia responds to recombinant human erythropoietin (rHuEPO) alone and in combination with recombinant human granulocyte-colony-stimulating factor (rHuGCSF) in 10% to 20% and in 35% to 40% of patients, respectively. We randomly divided 60 patients with low-grade anemic MDS and serum EPO levels lower than 500 IU/L (500 mU/mL) into 2 groups: rHuEPO + rHuG-CSF (arm A) and supportive care (arm B). After 12 weeks, those who had erythroid responses were given rHuEPO alone for 40 additional weeks. They were also given rHuG-CSF if they had relapses. A response was considered major if the hemoglobin (Hb) level was 115 g/L (11.5 g/dL) or higher and minor Hb increase was 15 g/L (1.5 g/dL) or more or if it remained stable without transfusion. Ten of 24 patients responded in arm A, and 0 of 26 responded in arm B (P =.01). Eight patients in arm A continued rHuEPO therapy alone, and 6 had relapses. Responses were always restored when rHuG-CSF was reintroduced. Mean direct costs per patient were 26,723 euros (arm A) and 8,746 euros (arm B). Quality of life was assessed with a Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale. Similar percentages of patients from both arms showed significant clinical improvement. rHuEPO plus rHuG-CSF led to responses in 41.7% of MDS patients. This treatment was expensive. No effect on quality of life was demonstrated.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:CasadevallNicoleN,
pubmed-author:ChomienneChristineC,
pubmed-author:DamajGandhiG,
pubmed-author:DombretHervéH,
pubmed-author:DreyfusFrançoisF,
pubmed-author:DuboisStéphanieS,
pubmed-author:DurieuxPierreP,
pubmed-author:FenauxPierreP,
pubmed-author:GiraudierStéphaneS,
pubmed-author:GuerciAgnèsA,
pubmed-author:GuyLaurentL,
pubmed-author:HemeryFrançoisF,
pubmed-author:LepageEricE,
pubmed-author:MaloiselFrédéricF,
pubmed-author:MarieJean-PierreJP,
pubmed-author:NavarroRobertR,
pubmed-author:QuarréMarie-CatherineMC,
pubmed-author:RibragVincentV,
pubmed-author:StamatoullasAspasiaA,
pubmed-author:VekhoffAnneA
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
104
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
321-7
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:15054036-Adult,
pubmed-meshheading:15054036-Aged,
pubmed-meshheading:15054036-Aged, 80 and over,
pubmed-meshheading:15054036-Anemia,
pubmed-meshheading:15054036-Cost-Benefit Analysis,
pubmed-meshheading:15054036-Drug Costs,
pubmed-meshheading:15054036-Erythropoietin,
pubmed-meshheading:15054036-Female,
pubmed-meshheading:15054036-Follow-Up Studies,
pubmed-meshheading:15054036-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:15054036-Humans,
pubmed-meshheading:15054036-Male,
pubmed-meshheading:15054036-Middle Aged,
pubmed-meshheading:15054036-Myelodysplastic Syndromes,
pubmed-meshheading:15054036-Quality of Life,
pubmed-meshheading:15054036-Recombinant Proteins,
pubmed-meshheading:15054036-Treatment Outcome
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
|
| pubmed:affiliation |
Hôtel Dieu, Service d'Hématologie Biologique, 1 place du parvis Notre Dame, 75004 Paris, France. nicole.casadevall@htd.ap-hop-paris.fr
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|